HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 24, 2016--
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical
company engaged in the discovery and development of new orally
administered treatments for Alzheimer’s disease and diabetes, today
announced that the company’s Chief Scientific Officer Carmen Valcarce,
Ph.D., will speak at the 11th Annual Peptide Therapeutics Symposium at
the Salk Institute for Biological Studies in La Jolla, California. Dr.
Valcarce will discuss vTv's oral GLP-1R program during a presentation
titled “Non- Peptide GLP-1 Receptor Agonists; From Idea to Medicine.”
The presentation is scheduled for 3:00pm on Thursday, October 27.
GLP-1R is a well validated target for the treatment of T2DM, with
multiple marketed injectable GLP-1 analogues/mimetics that provide
glycemic control and weight loss in Type 2 Diabetes patients. Although
several of these peptides targeting GLP-1 receptor have reached
blockbuster status, their use has been limited by two major factors: 1)
route of administration being injections and 2) unfavorable tolerability
profile that includes nausea and vomiting.
Recognizing these drawbacks, scientists at vTv Therapeutics (vTv) have
designed orally bioavailable small molecule (non-peptide) GLP-1R
agonists (TTP054 and TTP273) that have a favorable tolerability profile
being oral agents compared to the injectable GLP-1 analogues/mimetics.
The vTv GLP-1R agonists have demonstrated efficacy in nonclinical and
early stage clinical studies by improving glycemic control and reducing
body weight. Additionally, vTv’s compounds have shown an impressive
tolerability profile in the clinic.
The on-going Phase 2 LOGRA study is assessing the safety and efficacy of
TTP273 in Type 2 diabetic subjects on stable doses of metformin. The
previous Phase 1b trial of TTP273 showed robust effects on postprandial
and fasting glucose. In this study, all doses of TTP273 were well
tolerated with no serious adverse events or evidence of significant
gastrointestinal side effects. The LOGRA study is expected to read out
at the end of this year.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and Type 2 diabetes as well as
treatment of inflammatory disorders and the prevention of muscle
weakness.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005169/en/
Source: vTv Therapeutics
vTv Therapeutics
Investors
IR@vtvtherapeutics.com
or
Media
Nura
Strong, 336-841-0300 X164
PR@vtvtherapeutics.com
